ArticleInternational journal of cancer2026
Memory Cell and Antibody Responses Following a Single Versus Two Doses of Escherichia coli-Produced Vaccine Against Human Papillomavirus Types 16 and 18: A Real-World Study in Chinese Girls.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
A comprehensive profile of immunogenicity induced by a single dose of human papillomavirus (HPV) vaccination has yet to be presented. We report interim data from an ongoing non-interventional real-world study comparing the memory cell and antibody responses following single- and two-dose regimens of the Escherichia coli-produced HPV-16/18 vaccine in Chinese girls aged 9-14 years. HPV-16/18-specific neutralizing antibodies, IgG antibodies, and memory B- and T-cell responses were assessed and compared between the single-dose and two-dose groups. The results showed that among 492 per-protocol participants (298 two-dose; 194 single-dose), the median time from Dose 1 to blood sampling was 12.07 months. Single-dose neutralizing antibody seropositivity exceeded 90% for HPV-16 and approached 80% for HPV-18. The antibody avidity index of HPV-16 IgG after a single dose was non-inferior to that after two doses (lower bound of the geometric mean avidity ratio > 0.5). Both dosing schedules induced HPV-16/18-specific memory B- and T-cell responses with similar positivity and geometric means (p > 0.05). Therefore, a single dose of the E. coli-produced HPV-16/18 vaccine elicited robust antibody quantity and quality, with memory B- and T-cell responses comparable to those induced by two doses, supporting its potential for population-level implementation and contribution to the WHO target of vaccinating 90% of girls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.